We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
The Spectranetics Corp. (MM) | NASDAQ:SPNC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 38.45 | 38.45 | 38.50 | 0 | 01:00:00 |
Delaware | 000-19711 | 84-0997049 | ||||
(State or other jurisdiction | (Commission | (IRS Employer | ||||
of incorporation) | File Number) | Identification No.) |
9965 Federal Drive |
Colorado Springs, Colorado 80921 |
(Address of principal executive offices) (Zip Code) |
THE SPECTRANETICS | |||
CORPORATION | |||
Date: | February 19, 2015 | By: | /s/ Jeffrey A. Sherman |
Jeffrey A. Sherman | |||
Vice President, Deputy General Counsel and Corporate Secretary | |||
COMPANY CONTACT | INVESTOR CONTACT |
The Spectranetics Corporation | Westwicke Partners |
Guy Childs, Chief Financial Officer | Lynn Pieper |
(719) 633-8333 | (415) 202-5678 |
lynn.pieper@westwicke.com |
• | Revenue of $63.0 million, up 50% (51% constant currency1) |
• | Vascular Intervention revenue of $39.1 million grew 90% (91% constant currency) |
• | U.S. peripheral atherectomy revenue grew 30% |
• | AngioSculpt™ revenue of $14.7 million achieved |
• | Lead Management revenue of $18.5 million increased 14% (15% constant currency) |
• | U.S. revenue grew 52% to $52.3 million; International revenue grew 43% (49% constant currency) to $10.6 million |
• | Closed acquisition of Stellarex™ Drug Coated Balloon (DCB); Launched Stellarex in Europe in January 2015 |
• | Vascular Intervention revenue growth is anticipated to be in the range of 41% to 46%. This includes projected AngioSculpt revenue of $62 million to $66 million and projected ISR revenue of approximately $15 million to $20 million. |
• | Lead Management revenue growth is estimated in the range of 8% to 10%, which has been adjusted from the range of 11% to 12% provided previously, entirely due to the weaker euro. |
• | Gross margin is expected to be in the range of 74.5% to 75.0%. This includes improvement of approximately 50 basis points within the current business, which is offset by the dilutive impact of approximately 50 to 100 basis points associated with establishing manufacturing operations for the Stellarex product line. |
• | Research, development and other technology expenses are expected to be approximately 25.5% to 26.0% of revenue, revised from 15.5% to 16.0% provided previously. The increase is entirely due to costs associated with the Stellarex program. |
Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||
Revenue | $ | 62,959 | $ | 41,920 | $ | 204,914 | $ | 158,811 | ||||||||
Cost of products sold | 15,859 | 10,359 | 51,385 | 41,356 | ||||||||||||
Amortization of inventory step-up | 1,060 | — | 2,074 | — | ||||||||||||
Gross profit | 46,040 | 31,561 | 151,455 | 117,455 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 36,447 | 23,661 | 128,129 | 91,750 | ||||||||||||
Research, development and other technology | 9,311 | 5,760 | 28,675 | 22,080 | ||||||||||||
Acquisition transaction and integration costs | 9,233 | — | 17,288 | — | ||||||||||||
Medical device excise tax | 857 | 570 | 2,834 | 2,138 | ||||||||||||
Acquisition-related intangible asset amortization | 3,007 | 245 | 6,335 | 901 | ||||||||||||
Contingent consideration expense | 955 | 229 | 2,070 | 867 | ||||||||||||
Intangible asset impairment and change in fair value of contingent consideration liability, net | — | (675 | ) | 3,074 | (675 | ) | ||||||||||
Total operating expenses | 59,810 | 29,790 | 188,405 | 117,061 | ||||||||||||
Operating (loss) income | (13,770 | ) | 1,771 | (36,950 | ) | 394 | ||||||||||
Other (expense) income, net | (1,864 | ) | (3 | ) | (4,273 | ) | 16 | |||||||||
(Loss) income before taxes | (15,634 | ) | 1,768 | (41,223 | ) | 410 | ||||||||||
Income tax (benefit) expense | (903 | ) | 885 | (322 | ) | 780 | ||||||||||
Net (loss) income | $ | (14,731 | ) | $ | 883 | $ | (40,901 | ) | $ | (370 | ) | |||||
Net (loss) income per common share: | ||||||||||||||||
Basic and diluted | $ | (0.35 | ) | $ | 0.02 | $ | (0.98 | ) | $ | (0.01 | ) | |||||
Weighted average shares outstanding: | ||||||||||||||||
Basic | 41,931 | 41,108 | 41,679 | 38,941 | ||||||||||||
Diluted | 41,931 | 42,741 | 41,679 | 38,941 |
December 31, 2014 | December 31, 2013 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 95,505 | $ | 128,395 | |||
Accounts receivable, net | 41,090 | 26,766 | |||||
Inventories, net | 25,446 | 9,476 | |||||
Deferred income taxes, current portion, net | 2,200 | 445 | |||||
Other current assets | 8,093 | 2,748 | |||||
Total current assets | 172,334 | 167,830 | |||||
Property and equipment, net | 33,819 | 28,281 | |||||
Debt issuance costs, net | 6,912 | — | |||||
Goodwill and intangible assets | 252,514 | 20,455 | |||||
Other assets | 1,371 | 591 | |||||
Total assets | $ | 466,950 | $ | 217,157 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities | $ | 41,343 | $ | 23,225 | |||
Convertible senior notes | 230,000 | — | |||||
Other non-current liabilities | 33,450 | 3,932 | |||||
Stockholders’ equity | 162,157 | 190,000 | |||||
Total liabilities and stockholders’ equity | $ | 466,950 | $ | 217,157 |
THE SPECTRANETICS CORPORATION |
Supplemental Financial Information |
(Unaudited) |
Financial Summary | 2013 | 2014 | |||||||||||||||||
(000’s, except laser sales and installed base amounts) | 4th Qtr | 1st Qtr | 2nd Qtr | 3rd Qtr | 4th Qtr | ||||||||||||||
Disposable products revenue: | |||||||||||||||||||
Vascular Intervention revenue (organic) | $ | 20,555 | $ | 20,021 | $ | 22,496 | $ | 21,634 | $ | 24,371 | |||||||||
Vascular Intervention revenue (AngioSculpt) | — | — | — | 14,942 | 14,684 | ||||||||||||||
Total Vascular Intervention revenue | 20,555 | 20,021 | 22,496 | 36,576 | 39,055 | ||||||||||||||
Lead Management revenue | 16,286 | 14,470 | 16,114 | 17,569 | 18,509 | ||||||||||||||
Total disposable products revenue | 36,841 | 34,491 | 38,610 | 54,145 | 57,564 | ||||||||||||||
Laser, service, and other revenue | 5,079 | 5,123 | 4,945 | 4,641 | 5,395 | ||||||||||||||
Total revenue | 41,920 | 39,614 | 43,555 | 58,786 | 62,959 | ||||||||||||||
Non-GAAP gross margin percentage (excluding amortization of inventory step up) (1) | 75 | % | 74 | % | 76 | % | 75 | % | 75 | % | |||||||||
Net income (loss) | 883 | (5,661 | ) | (6,565 | ) | (13,944 | ) | (14,731 | ) | ||||||||||
Adjusted EBITDA (1) | 3,984 | (2,610 | ) | 777 | 2,742 | 3,249 | |||||||||||||
Cash flow provided by (used in) operating activities | 5,029 | (8,359 | ) | (1,111 | ) | (3,403 | ) | (7,576 | ) | ||||||||||
Total cash and cash equivalents at end of quarter | 128,395 | 120,866 | 107,027 | 103,538 | 95,505 | ||||||||||||||
Laser sales summary: | |||||||||||||||||||
Laser sales from inventory | 5 | 9 | 8 | 7 | 11 | ||||||||||||||
Laser sales from evaluation/rental units | 5 | 4 | 1 | 5 | 2 | ||||||||||||||
Total laser sales | 10 | 13 | 9 | 12 | 13 | ||||||||||||||
(1) Non-GAAP gross margin percentage (excluding amortization of inventory step up) and Adjusted EBITDA are non-GAAP financial measures. Please refer to the non-GAAP reconciliation tables following this table for the reconciliation to the most comparable GAAP measures. | |||||||||||||||||||
Worldwide Installed Base Summary: | |||||||||||||||||||
Laser sales from inventory | 5 | 9 | 8 | 7 | 11 | ||||||||||||||
Rental placements | 29 | 20 | 32 | 34 | 26 | ||||||||||||||
Evaluation placements | 9 | 8 | 6 | 11 | 8 | ||||||||||||||
Laser placements during quarter | 43 | 37 | 46 | 52 | 45 | ||||||||||||||
Buy-backs/returns during quarter | (18 | ) | (17 | ) | (15 | ) | (11 | ) | (10 | ) | |||||||||
Net laser placements during quarter | 25 | 20 | 31 | 41 | 35 | ||||||||||||||
Total lasers placed at end of quarter | 1,144 | 1,164 | 1,195 | 1,236 | 1,271 |
THE SPECTRANETICS CORPORATION | ||||||||||||||||||||
Reconciliation of revenue by geography to non-GAAP revenue by geography on a constant currency basis (in thousands, except percentages) (unaudited) | ||||||||||||||||||||
Three Months Ended | ||||||||||||||||||||
December 31, 2014 | December 31, 2013 | Change | ||||||||||||||||||
Revenue, as reported | Foreign exchange impact as compared to prior period | Revenue on a constant currency basis | Revenue, as reported | As reported | Constant currency basis | |||||||||||||||
United States | $ | 52,310 | $ | — | $ | 52,310 | $ | 34,493 | 52 | % | 52 | % | ||||||||
International | 10,649 | 417 | 11,066 | 7,427 | 43 | % | 49 | % | ||||||||||||
Total revenue | $ | 62,959 | $ | 417 | $ | 63,376 | $ | 41,920 | 50 | % | 51 | % |
Twelve Months Ended | ||||||||||||||||||||
December 31, 2014 | December 31, 2013 | Change | ||||||||||||||||||
Revenue, as reported | Foreign exchange impact as compared to prior period | Revenue on a constant currency basis | Revenue, as reported | As reported | Constant currency basis | |||||||||||||||
United States | $ | 167,399 | $ | — | $ | 167,399 | $ | 130,126 | 29 | % | 29 | % | ||||||||
International | 37,515 | (204 | ) | 37,311 | 28,685 | 31 | % | 30 | % | |||||||||||
Total revenue | $ | 204,914 | $ | (204 | ) | $ | 204,710 | $ | 158,811 | 29 | % | 29 | % |
THE SPECTRANETICS CORPORATION Reconciliation of revenue by product line to non-GAAP revenue by product line on a constant currency basis (in thousands, except percentages) (unaudited) | ||||||||||||||||||||
Three Months Ended | ||||||||||||||||||||
December 31, 2014 | December 31, 2013 | Change | ||||||||||||||||||
Revenue, as reported | Foreign exchange impact as compared to prior period | Revenue on a constant currency basis | Revenue, as reported | As reported | Constant currency basis | |||||||||||||||
Vascular Intervention | $ | 39,055 | $ | 108 | $ | 39,163 | $ | 20,555 | 90 | % | 91 | % | ||||||||
Lead Management | 18,509 | 208 | 18,717 | 16,286 | 14 | % | 15 | % | ||||||||||||
Laser System, Service & Other | 5,395 | 101 | 5,496 | 5,079 | 6 | % | 8 | % | ||||||||||||
Total revenue | $ | 62,959 | $ | 417 | $ | 63,376 | $ | 41,920 | 50 | % | 51 | % | ||||||||
Twelve Months Ended | ||||||||||||||||||||
December 31, 2014 | December 31, 2013 | Change | ||||||||||||||||||
Revenue, as reported | Foreign exchange impact as compared to prior period | Revenue on a constant currency basis | Revenue, as reported | As reported | Constant currency basis | |||||||||||||||
Vascular Intervention | $ | 118,148 | $ | (88 | ) | $ | 118,060 | $ | 75,601 | 56 | % | 56 | % | |||||||
Lead Management | 66,662 | (106 | ) | 66,556 | 62,518 | 7 | % | 6 | % | |||||||||||
Laser System, Service & Other | 20,104 | (10 | ) | 20,094 | 20,692 | (3 | )% | (3 | )% | |||||||||||
Total revenue | $ | 204,914 | $ | (204 | ) | $ | 204,710 | $ | 158,811 | 29 | % | 29 | % |
THE SPECTRANETICS CORPORATION | ||||||||||||||||
Reconciliation of gross margin to non-GAAP gross margin excluding amortization of inventory step-up (in thousands, except percentages) (unaudited) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31, 2014 | December 31, 2013 | December 31, 2014 | December 31, 2013 | |||||||||||||
Gross profit, as reported | $ | 46,040 | $ | 31,561 | $ | 151,455 | $ | 117,455 | ||||||||
Amortization of inventory step-up (1) | 1,060 | — | 2,074 | — | ||||||||||||
Adjusted gross profit, excluding amortization of inventory step-up | $ | 47,100 | $ | 31,561 | $ | 153,529 | $ | 117,455 | ||||||||
Gross margin percentage, as reported | 73 | % | 75 | % | 74 | % | 74 | % | ||||||||
Non-GAAP gross margin percentage, excluding amortization of inventory step-up | 75 | % | 75 | % | 75 | % | 74 | % |
Reconciliation of Net (Loss) Income to Non-GAAP Net (Loss) Income (in thousands) (unaudited) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31, 2014 | December 31, 2013 | December 31, 2014 | December 31, 2013 | |||||||||||||
Net (loss) income, as reported | $ | (14,731 | ) | $ | 883 | $ | (40,901 | ) | $ | (370 | ) | |||||
Acquisition transaction and integration costs (2) | 9,233 | — | 17,288 | — | ||||||||||||
Amortization of inventory step-up (1) | 1,060 | — | 2,074 | — | ||||||||||||
Acquisition-related intangible asset amortization (3) | 3,007 | 245 | 6,335 | 901 | ||||||||||||
Contingent consideration expense (4) | 955 | 229 | 2,070 | 867 | ||||||||||||
Intangible asset impairment and change in fair value of contingent consideration liability, net (5) | — | (675 | ) | 3,074 | (675 | ) | ||||||||||
Release of valuation allowance related to AngioScore acquisition (6) | (1,266 | ) | — | (1,266 | ) | — | ||||||||||
Non-GAAP net (loss) income | $ | (1,742 | ) | $ | 682 | $ | (11,326 | ) | $ | 723 |
THE SPECTRANETICS CORPORATION | ||||||||||||||||
Reconciliation of Net (Loss) Income Per Share to Non-GAAP Net (Loss) Income Per Share (unaudited) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31, 2014 | December 31, 2013 | December 31, 2014 | December 31, 2013 | |||||||||||||
Net (loss) income per share, as reported | $ | (0.35 | ) | $ | 0.02 | $ | (0.98 | ) | $ | (0.01 | ) | |||||
Acquisition transaction and integration costs (2) | 0.22 | — | 0.41 | — | ||||||||||||
Amortization of inventory step-up (1) | 0.03 | — | 0.05 | — | ||||||||||||
Acquisition-related intangible asset amortization (3) | 0.07 | 0.01 | 0.15 | 0.02 | ||||||||||||
Contingent consideration expense (4) | 0.02 | 0.01 | 0.05 | 0.02 | ||||||||||||
Intangible asset impairment and change in fair value of contingent consideration liability, net (5) | — | (0.02 | ) | 0.07 | (0.02 | ) | ||||||||||
Release of valuation allowance due to AngioScore acquisition (6) | (0.03 | ) | — | (0.03 | ) | — | ||||||||||
Non-GAAP net (loss) income per share (7) | $ | (0.04 | ) | $ | 0.02 | $ | (0.27 | ) | $ | 0.02 |
Reconciliation of Net Income (Loss) to Adjusted EBITDA (in thousands) (unaudited) | ||||||||||||||||||||
Three Months Ended | ||||||||||||||||||||
Dec 31, 2013 | March 31, 2014 | June 30, 2014 | Sept 30, 2014 | Dec 31, 2014 | ||||||||||||||||
Net income (loss), as reported | $ | 883 | $ | (5,661 | ) | $ | (6,565 | ) | $ | (13,944 | ) | $ | (14,731 | ) | ||||||
Income tax expense (benefit) | 885 | 147 | 246 | 188 | (903 | ) | ||||||||||||||
Interest (income) expense, net | (2 | ) | (1 | ) | 489 | 1,801 | 1,773 | |||||||||||||
Depreciation and amortization | 2,419 | 2,459 | 2,473 | 2,691 | 2,855 | |||||||||||||||
Acquisition transaction and integration costs (2) | — | 271 | 3,958 | 3,826 | 9,233 | |||||||||||||||
Amortization of inventory step-up (1) | — | — | — | 1,014 | 1,060 | |||||||||||||||
Acquisition-related intangible asset amortization (3) | 245 | 137 | 136 | 3,055 | 3,007 | |||||||||||||||
Contingent consideration expense (4) | 229 | 38 | 40 | 1,037 | 955 | |||||||||||||||
Intangible asset impairment and change in fair value of contingent consideration liability, net (5) | (675 | ) | — | — | 3,074 | — | ||||||||||||||
Adjusted EBITDA (8) | $ | 3,984 | $ | (2,610 | ) | $ | 777 | $ | 2,742 | $ | 3,249 |
THE SPECTRANETICS CORPORATION Reconciliation of Net Loss to Adjusted EBITDA (in thousands) (unaudited) | ||||||||
Twelve Months Ended | ||||||||
December 31, 2014 | December 31, 2013 | |||||||
Net loss, as reported | $ | (40,901 | ) | $ | (370 | ) | ||
Income tax (benefit) expense | (322 | ) | 780 | |||||
Interest expense (income), net | 4,062 | (3 | ) | |||||
Depreciation and amortization | 10,478 | 9,705 | ||||||
Acquisition transaction and integration costs (2) | 17,288 | — | ||||||
Amortization of inventory step-up (1) | 2,074 | — | ||||||
Acquisition-related intangible asset amortization (3) | 6,335 | 901 | ||||||
Contingent consideration expense (4) | 2,070 | 867 | ||||||
Intangible asset impairment and change in fair value of contingent consideration liability, net (5) | 3,074 | (675 | ) | |||||
Adjusted EBITDA (8) | $ | 4,158 | $ | 11,205 |
Reconciliation of 2015 Projected Net Loss to Non-GAAP Projected Net Loss (in millions) (unaudited) | ||||||||
Projected Range | ||||||||
Twelve Months Ending | ||||||||
December 31, 2015 | December 31, 2015 | |||||||
Net loss, GAAP | $ | (62.0 | ) | $ | (58.0 | ) | ||
Acquisition-related transaction and integration costs (9) | 9.0 | 9.0 | ||||||
Acquisition-related amortization & contingent consideration expense (10) | 17.1 | 17.1 | ||||||
Non-GAAP net loss | $ | (35.9 | ) | $ | (31.9 | ) |
Reconciliation of 2015 Projected Net Loss Per Share to Non-GAAP Projected Net Loss Per Share (unaudited) | ||||||||
Projected Range | ||||||||
Twelve Months Ending | ||||||||
December 31, 2015 | December 31, 2015 | |||||||
Net loss per share, GAAP | $ | (1.46 | ) | $ | (1.36 | ) | ||
Acquisition-related transaction and integration costs (9) | 0.21 | 0.21 | ||||||
Acquisition-related amortization & contingent consideration expense (10) | 0.40 | 0.40 | ||||||
Non-GAAP net loss per share (7) | $ | (0.84 | ) | $ | (0.75 | ) |
1) | Amortization of inventory step-up relates to the inventory acquired in the AngioScore acquisition. |
2) | Acquisition transaction and integration costs in 2014 primarily relate to the AngioScore acquisition, which closed on June 30, 2014, and include investment banking fees, accounting, consulting, and legal fees. In the third and fourth quarters of 2014, integration costs also included severance and retention costs. In addition, these costs included $1.2 million and $5.6 million during the third and fourth quarters of 2014, respectively, for legal fees associated with a patent-related matter in which AngioScore is the plaintiff. In the fourth quarter of 2014, transaction and integration costs also included $1.5 million, primarily legal fees, related to the Stellarex™ acquisition, which closed on January 27, 2015. |
3) | Acquisition-related intangible asset amortization relates to intangible assets acquired in the AngioScore acquisition in June 2014 and intangible assets acquired from Upstream Peripheral Technologies Ltd. (“Upstream”) in 2013. |
4) | Contingent consideration expense represents the accretion of the estimated contingent consideration liability related to future amounts payable to former AngioScore stockholders primarily based on sales of the AngioScore products and achievement of product development milestones, and to Upstream, primarily based on sales of the products acquired. |
5) | Intangible asset impairment and change in fair value of contingent consideration liability, net, relates to intangible assets and contingent consideration liability acquired from Upstream. Due to factors associated with the access and overall retrograde interventional market and other relevant factors, in the third quarter of 2014, we recorded a net charge of $3.1 million, consisting of an impairment charge of approximately $4.1 million related to the intangible assets acquired and a reduction to the contingent consideration liability of $1.0 million. In the fourth quarter of 2013, we recorded a net credit of $0.7 million, consisting of a reduction to the contingent consideration liability of approximately $5.2 million and an impairment charge of approximately $4.5 million related to the intangible assets acquired. |
6) | Included in the $0.3 million income tax benefit for the year ended December 31, 2014 is a $1.3 million tax benefit from the release of valuation allowance of our deferred tax assets (“DTAs”). In connection with our acquisition of AngioScore during the year ended December 31, 2014, deferred tax liabilities (“DTLs”) were established for the book-tax basis differences related to the non-goodwill intangible assets. These DTLs exceeded the acquired DTAs by $1.3 million. |
7) | Per share amounts may not add due to rounding. |
8) | In 2014, we are not adding back the medical device excise tax to Adjusted EBITDA, as the tax was also included in the 2013 results. Therefore, 2013 Adjusted EBITDA has been restated to include the medical device excise tax. |
9) | Acquisition-related transaction and integration costs include AngioScore severance and retention costs of $2.1 million, legal fees associated with a patent-related matter in which AngioScore is the plaintiff of $4.9 million and estimated transaction and integration costs for the Stellarex acquisition of $2.0 million. |
10) | Acquisition-related intangible asset amortization relates to intangible assets acquired in the AngioScore acquisition in June 2014 and the Stellarex acquisition in January 2015, intangible assets acquired from Upstream, and amortization of acquired inventory step-up related to the inventory acquired in the AngioScore acquisition. Contingent consideration expense represents the accretion of the estimated contingent consideration liability related to future amounts that may be payable to former AngioScore stockholders primarily based on sales of the AngioScore products and achievement of product development milestones, and to Upstream, primarily based on sales of the products acquired. |
• | Management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures used. |
• | Depreciation and amortization expense, while not requiring cash settlement, are ongoing and recurring expenses and have a material impact on GAAP net income or loss and reflect costs to us not reflected in Adjusted EBITDA. The intangible asset impairment, while not requiring cash settlement, reflects an economic cost to us not reflected in Adjusted EBITDA. |
• | Items such as the acquisition transaction and integration costs and contingent consideration expense excluded from Adjusted EBITDA and non-GAAP net (loss) income can have a material impact on cash flows and GAAP net (loss) income and reflect economic costs to us not reflected in Adjusted EBITDA or non-GAAP net (loss) income. |
• | Revenue growth rates stated on a constant currency basis, by their nature, exclude the impact of changes in foreign currency exchange rates, which may have a material impact on GAAP revenue. |
• | Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. |
1 Year The Spectranetics Corp. (MM) Chart |
1 Month The Spectranetics Corp. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions